Skip to main content
. 2024 Mar 22;3(7):101859. doi: 10.1016/j.jscai.2024.101859

Table 1.

Main characteristics of the included trials.

Trial Enrollment years Country ACSa DMb SAPT Stent Experimental
 Control
Sized DAPT Sized DAPT
HOST-IDEA23 2016-2021 South Korea 55.2% 39% Anyc Biodegradable or polymer-free SES 406 3 mo 378 12 mo
MASTER DAPT30 2017-2019 Multinational 48.3% 34% Clopidogrel, aspirin SES 754 1 mo 784 6 mo
TICO26 2015-2018 South Korea 100% 27% Ticagrelor SES 418 3 mo 417 12 mo
SMART-CHOICE22 2014-2017 South Korea 58.2% 38% Clopidogrel EES, SES 923 3 mo 899 12 mo
TWILIGHT28 2015-2017 Multinational 64.8% 37% Ticagrelor Second-generation DESe 570 3 mo 552 12 mo
STOPDAPT-236 2015-2017 Japan 38.2% 39% Clopidogrel Cobalt-chromium EES 1303 1 mo 1317 12 mo
REDUCE19 2014-2016 Multinational 100% 21% Aspirin CD34+ antibody-coated SES 1018 3 mo 1012 12 mo
GLOBAL LEADERS37 2013-2015 Multinational 50.6% 24% Ticagrelor BES 162 1 mo 145 12 mo
SMART-DATE34 2012-2015 South Korea 100% 28% Aspirin ZES, EES, BES 378 6 mo 365 12 mo
IVUS-XPL38 2010-2014 South Korea 49.0% 37% Aspirin EES 211 6 mo 203 12 mo
SECURITY32 2009-2014 Multinational 38.4% 31% Aspirin ZES, BES, EES 249 6 mo 257 12 mo
ISAR-SAFE29 2008-2014 Multinational 40.7% 25% Aspirin EES, SES, ZES, BES, PES 206 6 mo 223 12 mo
I-LOVE-IT 224 2012-2013 China 81.8% 23% Aspirin Biodegradable-polymer SES 495 6 mo 484 12 mo
OPTIMIZE35 2010-2012 Brazil 32.0% 34% Aspirin ZES 554 3 mo 549 12 mo
RESET27 2009-2010 South Korea 54.6% 29% Aspirin ZES 316 3 mo 305 12 mo
EXCELLENT21 2008-2009 South Korea 48.5% 38% Aspirin EES, SES 269 6 mo 281 12 mo

ACS, acute coronary syndrome; BES, biolimus-eluting stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; PES, paclitaxel-eluting stent; SAPT, single antiplatelet therapy; SES, sirolimus-eluting stent; ZES, zotarolimus-eluting stent.

a

Average of the percentage of acute coronary syndrome in abbreviated and standard dual antiplatelet groups.

b

Percentage of patients with diabetes in the total sample of the original trial.

c

Any antiplatelet at the discretion of the ordering physician: aspirin (64.1%), clopidogrel (33.7%), ticagrelor (1.9%), prasugrel (0.3%) in the trial.

d

Sample size of the population with diabetes mellitus.

e

Second-generation drug-eluting stent: durable polymer cobalt-chromium EES, durable polymer platinum-chromium EES, durable polymer ZES, durable polymer cobalt-chromium SES, biodegradable polymer DES, polymer-free DES, bioresorbable vascular scaffold, sirolimus-eluting self-apposing stent, tacrolimus-eluting carbostent.